Literature DB >> 8598469

Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response.

B M Mitchell1, J G Stevens.   

Abstract

Neuroinvasiveness is a property central to the pathogenesis of herpes simplex virus (HSV) and most isolates demonstrate this property. Exceptions are HSV strains KOS and ANG, for which we have previously shown that the non-neuroinvasive phenotype is referable to single amino acid changes in glycoprotein D for ANG or glycoprotein B for KOS. Because glycoproteins B and D are immunologically significant, the possibility that the phenotype has an immunologic basis was examined. Nonimmunosuppressed mice could not be killed with any dose of these non-neuroinvasive viruses after footpad inoculation, but in cyclophosphamide-suppressed animals, the ratios of plaque-forming units to LD50 decreased by at least four orders of magnitude to levels comparable with that of ANG-path, a neuroinvasive derivative of ANG. KOS and ANG induced a more rapid circulating neutralizing Ab response than did ANG-path, and mice were protected when these agents were co-infected with the neuroinvasive strain. The noninvasive viruses engendered an enhanced mononuclear cell infiltrate in infected spinal ganglia which consisted of increased numbers of CD4+ and CD8+ T cells and an increased production and secretion of IgG. HSV-specific Ab-secreting cells were also observed. In addition, passive transfer of anti-HSV mouse serum protected immunosuppressed mice from lethal HSV challenge. Selective in vivo depletion of T lymphocytes increased the detectable levels of both KOS and ANG viruses in the spinal ganglia at 6 days postinfection, but it did not alter the ratios of plaque-forming units to LD50 or affect the HSV-induced increase in ganglionic IgG. Taken together, these data indicate that in these systems there is an immunologic basis for the control of HSV-1 neuroinvasiveness and that humoral, rather than cell-mediated immunity, is playing the major role.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8598469

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Description of a nonlethal herpes simplex virus type 1 glycoprotein D deletion mutant affecting a site frequently used for PCR.

Authors:  P V Coyle; S Jain; D Wyatt; C McCaughey; H J O'Neill
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules.

Authors:  Elisabeth Sievers; Jürgen Neumann; Martin Raftery; Günther SchOnrich; Anna Maria Eis-Hübinger; Norbert Koch
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

3.  Intracellular trafficking and maturation of herpes simplex virus type 1 gB and virus egress require functional biogenesis of multivesicular bodies.

Authors:  Arianna Calistri; Paola Sette; Cristiano Salata; Enrico Cancellotti; Cristina Forghieri; Alessandra Comin; Heinrich Göttlinger; Gabriella Campadelli-Fiume; Giorgio Palù; Cristina Parolin
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

4.  Innate recognition network driving herpes simplex virus-induced corneal immunopathology: role of the toll pathway in early inflammatory events in stromal keratitis.

Authors:  Pranita P Sarangi; Bumseok Kim; Evelyn Kurt-Jones; Barry T Rouse
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

5.  Herpes Simplex Virus 1 Replication, Ocular Disease, and Reactivations from Latency Are Restricted Unilaterally after Inoculation of Virus into the Lip.

Authors:  Nolwenn Poccardi; Antoine Rousseau; Oscar Haigh; Julie Takissian; Thierry Naas; Claire Deback; Louise Trouillaud; Mohammad Issa; Simon Roubille; Franceline Juillard; Stacey Efstathiou; Patrick Lomonte; Marc Labetoulle
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

Review 6.  Experimental investigation of herpes simplex virus latency.

Authors:  E K Wagner; D C Bloom
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

7.  Intrastrain variants of herpes simplex virus type 1 isolated from a neonate with fatal disseminated infection differ in the ICP34.5 gene, glycoprotein processing, and neuroinvasiveness.

Authors:  J R Bower; H Mao; C Durishin; E Rozenbom; M Detwiler; D Rempinski; T L Karban; K S Rosenthal
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.

Authors:  Maria A Thomas; Jacqueline F Spencer; Karoly Toth; John E Sagartz; Nancy J Phillips; William S M Wold
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

9.  Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice.

Authors:  K Olson; P Macias; S Hutton; W A Ernst; G Fujii; J P Adler-Moore
Journal:  Vaccine       Date:  2009-10-14       Impact factor: 3.641

10.  Effects of mutations in the cytoplasmic domain of herpes simplex virus type 1 glycoprotein B on intracellular transport and infectivity.

Authors:  Igor Beitia Ortiz de Zarate; Karin Kaelin; Flore Rozenberg
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.